中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [525]
昆明植物研究所 [155]
西北高原生物研究所 [63]
上海生物化学与细胞... [56]
过程工程研究所 [38]
化学研究所 [36]
更多
采集方式
OAI收割 [1227]
iSwitch采集 [51]
内容类型
期刊论文 [1225]
学位论文 [42]
会议论文 [11]
发表日期
2023 [40]
2022 [47]
2021 [45]
2020 [48]
2019 [72]
2018 [91]
更多
学科主题
Oncology [37]
Pharmacol... [37]
Chemistry [26]
Chemistry... [23]
生命有机化学 [20]
Biochemis... [17]
更多
筛选
浏览/检索结果:
共1278条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
ANTITUMOR ACTIVITY OFGYTOGHALASIN D
期刊论文
OAI收割
JOURNAL OF ANTIBIOTICS, 2025, 页码: 722-723
作者:
Wen-Jie Guo
;
Guan-Jun Tao
;
Wen-Yi Tao
;
Feng-Jie Cui
;
Xian-Chun Jin
  |  
收藏
  |  
浏览/下载:200/0
  |  
提交时间:2017/07/19
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
d
]pyrimidin-7(6
H
)-one" Scaffold for the Treatment of B Cell Lymphoma
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 4, 页码: 2884-2906
作者:
Liang, Xuewu
;
Yu, Haolan
;
Liang, Renwen
;
Feng, Zhuanghui
;
Saidahmatov, Abdusaid
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2024/04/09
pH-responsive nanogels with enhanced antioxidant and antitumor activities on drug delivery and smart drug release
期刊论文
OAI收割
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 卷号: 257, 页码: 16
作者:
Ma, Bing
;
Li, Qing
;
Mi, Yingqi
;
Zhang, Jingjing
;
Tan, Wenqiang
  |  
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2024/01/26
Benzimidazole-chitosan quaternary ammonium
salt
Nanogels
pH-responsive
Antioxidant activity
Antitumor activity
PRMT1 Inhibition Activates the Interferon Pathway to Potentiate Antitumor Immunity and Enhance Checkpoint Blockade Efficacy in Melanoma
期刊论文
OAI收割
CANCER RESEARCH, 2024, 卷号: 84, 期号: 3, 页码: 419-433
作者:
Tao, Hongru
;
Jin, Chen
;
Zhou, Liyuan
;
Deng, Zhenzhong
;
Li, Xiao
  |  
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2024/04/09
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
期刊论文
OAI收割
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 卷号: 127, 页码: 14
作者:
Zhang, Hui
;
Hu, Ke
;
Lu, Yumeng
;
Xu, Zhijian
;
Chen, Gege
  |  
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2024/03/25
Multiple myeloma
M1 macrophages
Th1 cells
Immunomodulatory
Discovery, Optimization, and Evaluation of Novel Pyridin-2(1
H
)-one Analogues as Potent TRK Inhibitors for Cancer Treatment
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 2, 页码: 1168-1183
作者:
Xu, Zichao
;
Peng, Xia
;
Zhang, Renjie
;
Ji, Yinchun
;
You, Mengke
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2024/02/27
SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2024, 页码: 10
作者:
Li, Wen-jing
;
Xie, Cheng-ying
;
Zhu, Xi
;
Tang, Jiao
;
Wang, Lei
  |  
收藏
  |  
浏览/下载:2/0
  |  
提交时间:2024/02/19
SIBP-03
HER3
HER3-targeted therapy
neuregulin 1
EGFR
HER2
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
G12D
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 2, 页码: 1147-1167
作者:
Zhou, Chuan
;
Fan, Zisheng
;
Gu, Yuejiao
;
Ge, Zhiming
;
Tao, Zhaofan
  |  
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2024/02/27
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2023, 页码: 18
作者:
Chen, Yi
;
Liu, Qiu-pei
;
Xie, Hua
;
Ding, Jian
  |  
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2024/01/16
KRAS mutation
KRAS(G12C) inhibitor
Pan-KRAS inhibitor
SHP2 allosteric inhibitor
SOS1 inhibitor
combination therapy
Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma
期刊论文
OAI收割
ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4748-4764
作者:
Liu, Yingqiang
;
Zhan, Zhengsheng
;
Kang, Zhuang
;
Li, Mengyuan
;
Lv, Yongcong
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2024/01/26
Small molecule inhibitor
Tumor microenvironment
Immune-checkpoint
immune-deficient mouse models
including temozolomide (TMZ) insensitive tumors. Notably